an increasing trendp<0.05
All three cell subsets showed an increasing trend in pAkt in post-dosing in samples from the clinical non-responders, which was significant for CD14 + cells (p<0.05).
All three cell subsets showed an increasing trend in pAkt in post-dosing in samples from the clinical non-responders, which was significant for CD14 + cells (p<0.05).
We noted a consistent increase in phosphorylated p38, STAT1 and STAT3 in monocytes, with most of these changes being highly significant in samples from both clinical trials with tremelimumab.
The fact that most results are evident and concordant in both series, but more likely to be significant in the larger GA sample set, turns us to believe that the difference in the number of patients (6 compared to 21) may be the major factor responsible for the differences in statistically significant results.